Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
Accolade, Inc. (Nasdaq: ACCD) is a pioneering Personalized Healthcare company devoted to providing exceptional healthcare experiences to millions of people and their families, enabling them to live their healthiest lives. Accolade's range of solutions targets employers, health plans, and consumers by integrating virtual primary care, mental health services, expert medical opinions, and top-tier care navigation. Their innovative platform leverages cloud-based intelligent technology, coupled with expert clinical teams, including registered nurses, physician medical directors, pharmacists, and primary care physicians, to deliver comprehensive advocacy and healthcare services.
The company has been recognized for its significant contributions to the healthcare industry, such as being named one of Forbes' 25 most promising companies and achieving a spot on Inc. 500's list of America's fastest-growing private companies. Accolade's mission is to guide individuals through the complexities of the healthcare system, thereby enhancing outcomes and reducing costs for employers and health plans.
Accolade has recently gained considerable attention for its impressive 227% revenue growth, attributed to a relentless focus on delivering exceptional outcomes. This achievement earned Accolade a place in the Deloitte Technology Fast 500™ list for 2023. CEO Rajeev Singh credits the company's innovative approach and dedicated team for this remarkable performance.
Accolade's Trusted Partner Ecosystem, launched in 2019, exemplifies its commitment to comprehensive healthcare solutions. This ecosystem includes partnerships with leading companies like Kindbody and Noom, expanding access to specialized services such as fertility and metabolic health.
Accolade's financial health remains robust, with recent quarterly results showcasing a significant reduction in net loss and positive adjusted EBITDA, indicating a promising trajectory toward sustainable growth and profitability.
With a consumer satisfaction rating consistently over 90%, Accolade is steadily advancing its vision of transforming healthcare through predictive engagement, proactive care, and by addressing barriers to access and continuity of care. The company's forward-thinking approach ensures it remains at the forefront of healthcare innovation, making a significant impact on the industry and the lives of the people it serves.
For more information, visit accolade.com.
Accolade, Inc. (NASDAQ: ACCD) participated in the William Blair Healthcare 2021 Focus List Event on December 17, 2020. Rajeev Singh, CEO, delivered a fireside chat presentation, discussing Accolade's innovative healthcare solutions. The company specializes in personalized, technology-driven health and benefits solutions that empower individuals to navigate their healthcare systems effectively. With a remarkable NPS of 60 and consumer satisfaction rates exceeding 90%, Accolade aims to simplify healthcare for employees while reducing associated costs.
Accolade, Inc. (NASDAQ: ACCD) will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020. This event includes a fireside chat presentation. Participants can access an audio replay and related materials on ir.accolade.com. Accolade provides personalized health solutions that empower individuals to navigate the healthcare system effectively, boasting consumer satisfaction ratings over 90% and a net promoter score of 60.
Accolade, Inc. (NASDAQ: ACCD) will participate in the virtual 29th Annual Credit Suisse Healthcare Conference on November 11, 2020, at 10:15 a.m. E.T. The event includes a fireside chat presentation. Audio webcast and materials will be available on their investor relations website. Accolade offers personalized health solutions using technology to help users navigate healthcare and benefits with ease, maintaining over 90% consumer satisfaction and an NPS of 60.
Accolade, Inc. (Nasdaq: ACCD) announced the closing of its public offering of 5,750,000 shares of common stock at $38.50 per share, raising approximately $221.4 million in gross proceeds. This includes the full exercise of the underwriters' option to purchase an additional 750,000 shares. The offering was managed by Goldman Sachs, Morgan Stanley, and BofA Securities, among others. The funds will support Accolade's growth in personalized health solutions, aiding individuals in navigating the healthcare system.
Accolade, Inc. announced a public offering of 5,000,000 shares of common stock priced at $38.50 each, with an anticipated closing date of October 26, 2020. The underwriters have an option to purchase an additional 750,000 shares. Proceeds will be allocated for general corporate purposes, including working capital, operating expenses, and strategic investments. Goldman Sachs, Morgan Stanley, and BofA Securities are the joint book-running managers for the offering.
Accolade has filed a registration statement with the SEC for a public offering of 4,500,000 shares of common stock, with an option for underwriters to purchase an additional 675,000 shares. The offering price is yet to be determined and is subject to market conditions. Proceeds will be used for general corporate purposes including working capital, operating expenses, and strategic investments. Joint book-running managers include Goldman Sachs, Morgan Stanley, and BofA Securities. The registration statement is pending effectiveness.
Accolade, Inc. reported fiscal Q2 2021 revenue of $36.8 million, reflecting a 24% increase from $29.7 million in Q2 2020, fueled by rising customer additions across various segments. Despite ongoing challenges from the COVID-19 pandemic, CEO Rajeev Singh emphasized the company's strong financial performance and positive momentum. Notably, adjusted gross profit grew 23% to $15.9 million. However, the company experienced a net loss of $15.4 million, slightly higher than the previous year's $15 million loss. The outlook for the full year has been raised, indicating confidence in future growth.
Accolade (NASDAQ: ACCD) will release its fiscal Q2 2021 financial results on October 14, 2020, after markets close. The company will host a conference call at 5:00 p.m. EDT on the same day to discuss the results. Accolade offers personalized health solutions, assisting users in navigating the healthcare system and workplace benefits. The company boasts over 90% consumer satisfaction and a Net Promoter Score of 60, emphasizing its commitment to enhancing healthcare experiences.
FAQ
What is the current stock price of Accolade (ACCD)?
What is the market cap of Accolade (ACCD)?
What does Accolade, Inc. do?
How has Accolade performed financially recently?
What is the Trusted Partner Ecosystem?
Who are Accolade's key partners?
What recognition has Accolade received?
What is Accolade's mission?
How does Accolade contribute to healthcare cost reduction?
How does Accolade engage with its members?
What is Accolade's customer satisfaction rating?
Where can I find more information about Accolade?
